Drug Profile


Alternative Names: ABL 001

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Pyrazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myeloid leukaemia
  • Phase I Acute lymphoblastic leukaemia

Most Recent Events

  • 06 Sep 2017 Phase-III clinical trials in Chronic myeloid leukaemia (Second-line therapy or greater) in Canada, Spain, France, Germany (PO) (EudraCT2016-002461-66) (NCT03106779)
  • 23 Jun 2017 Novartis Pharmaceuticals completes a phase I pharmacokinetics trial in USA (PO) (NCT02857868)
  • 21 Apr 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top